Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Flow cytometry antibodies used.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Flow Cytometry, In Vivo, In Vitro

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Murlentamab opsonization of SKOV3-R2 + orients naïve macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1β, IL12, TNFα, IL6, IFNγ, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Labeling, Cell Culture, Derivative Assay, Expressing, Membrane, Flow Cytometry, Co-Culture Assay

Journal: FEBS letters

Article Title: The intracellular domain of the human protocadherin hFat1 interacts with Homer signalling scaffolding proteins.

doi: 10.1016/j.febslet.2006.08.079

Figure Lengend Snippet: Fig. 5. Co-localisation of hFat1 and Homer proteins in HeLa cells. (A) A truncated transmembrane form of hFat1 in C-terminal fusion with EGFP (Fat1-TEX-EGFP) and haemaglutinin-tagged Homer 3 (Homer-3-HA) were co-expressed. Left: EGFP fluorescence; middle: HA-immunofluores- cence (Alexa 594); right: merged images plus nuclear staining. The arrows indicate typical spots of co-localisation in a cellular protrusion and at the plasma membrane. (B) Colocalisation of endogenous hFat1 (left, stained with a monospecific antiserum, see Section 2) and Homer-3-fused to ECFP (middle). Right: Merged images plus nuclear staining. The arrows point to the plasma membrane. Lower panel: co-localisation of endogenous hFat1 and expressed Homer-3 in a cellular process.

Article Snippet: Fat1 was probed with the antiserum described in 2.2, Homer with monoclonal Ab sc-17842 (Santa Cruz).

Techniques: Staining, Clinical Proteomics, Membrane